JP2013529637A5 - - Google Patents

Download PDF

Info

Publication number
JP2013529637A5
JP2013529637A5 JP2013516636A JP2013516636A JP2013529637A5 JP 2013529637 A5 JP2013529637 A5 JP 2013529637A5 JP 2013516636 A JP2013516636 A JP 2013516636A JP 2013516636 A JP2013516636 A JP 2013516636A JP 2013529637 A5 JP2013529637 A5 JP 2013529637A5
Authority
JP
Japan
Prior art keywords
solid dispersion
phenoxymethyl
tetrazol
thiazol
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013516636A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013529637A (ja
JP5847813B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/040972 external-priority patent/WO2011163090A1/en
Publication of JP2013529637A publication Critical patent/JP2013529637A/ja
Publication of JP2013529637A5 publication Critical patent/JP2013529637A5/ja
Application granted granted Critical
Publication of JP5847813B2 publication Critical patent/JP5847813B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013516636A 2010-06-23 2011-06-17 5−エチル−2−{4−[4−(4−テトラゾル−1−イル−フェノキシメチル)−チアゾール−2−イル]−ピペリジン−1−イル}−ピリミジンの組成物 Expired - Fee Related JP5847813B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35798110P 2010-06-23 2010-06-23
US61/357,981 2010-06-23
PCT/US2011/040972 WO2011163090A1 (en) 2010-06-23 2011-06-17 Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine

Publications (3)

Publication Number Publication Date
JP2013529637A JP2013529637A (ja) 2013-07-22
JP2013529637A5 true JP2013529637A5 (enExample) 2014-08-07
JP5847813B2 JP5847813B2 (ja) 2016-01-27

Family

ID=44584703

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013516636A Expired - Fee Related JP5847813B2 (ja) 2010-06-23 2011-06-17 5−エチル−2−{4−[4−(4−テトラゾル−1−イル−フェノキシメチル)−チアゾール−2−イル]−ピペリジン−1−イル}−ピリミジンの組成物

Country Status (8)

Country Link
US (2) US9241924B2 (enExample)
EP (1) EP2585048B1 (enExample)
JP (1) JP5847813B2 (enExample)
CN (2) CN109674753A (enExample)
BR (1) BR112012032248A2 (enExample)
CA (1) CA2802541A1 (enExample)
ES (1) ES2676209T3 (enExample)
WO (1) WO2011163090A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP2185544B1 (en) 2007-07-19 2014-11-26 Cymabay Therapeutics, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 for the treatment of diabetes and metabolic disorders
CA2719507C (en) * 2008-03-31 2018-03-27 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
EP2483281B1 (en) 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
BR112012032248A2 (pt) 2010-06-23 2016-09-13 Metabolex Inc composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
CA2935307C (en) * 2013-12-31 2023-05-09 Ascendia Pharmaceuticals, Llc Pharmaceutical compositions for poorly water-soluble compounds
ES2753582T3 (es) * 2014-06-11 2020-04-13 Bayer Cropscience Ag Preparación de piperidin-4-carbotioamida
WO2018026890A1 (en) * 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ,インク. Ampkアクチベーター

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3108117A (en) 1959-02-12 1963-10-22 Mead Johnson & Co 3-benzyl-1, 2-diloweralkyl-3-pyrrolidinols
US3778443A (en) 1969-02-13 1973-12-11 Ciba Geigy Ag 4-tetrahydro pyridyl,hydroxy alkyl pyrazoles
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2701705A1 (de) 1976-01-28 1977-08-04 Sandoz Ag Neue organische verbindungen, ihre verwendung und herstellung
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP2527107B2 (ja) * 1991-04-16 1996-08-21 日本新薬株式会社 固体分散体の製造方法
US5817667A (en) 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
AU4444393A (en) 1992-09-01 1994-03-10 Zeneca Limited Pyrrolidine derivatives
GB9310713D0 (en) 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
ATE279406T1 (de) 1995-01-12 2004-10-15 Glaxo Group Ltd Piperidinderivate mit tachykinin-antagonistischer wirkung
US6048876A (en) 1995-01-23 2000-04-11 Suntory Limited Medicament for the alleviation or treatment of symptom derived from ischemic disease and compound useful therefor
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
KR100384979B1 (ko) 1995-09-07 2003-10-17 에프. 호프만-라 로슈 아게 심부전증및신부전증치료용의신규한4-(옥시알콕시페닐)-3-옥시-피페리딘
JPH11513382A (ja) 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング 5員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
KR100537843B1 (ko) 1996-07-22 2006-04-28 다이이치 아스비오파마 가부시키가이샤 아릴피페리디놀및아릴피페리딘유도체및이들을함유하는약제
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
US6274735B1 (en) 1998-08-10 2001-08-14 Hoffmann-La Roche Inc. Process and intermediates for preparation of substituted piperidines
IT1303737B1 (it) 1998-11-11 2001-02-23 Smithkline Beecham Spa Derivati fenilpiperidinici procedimento per la loro preparazione eloro uso come ligandi del recettore orl-1.
US20030017528A1 (en) 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
PT1133559E (pt) 1998-11-20 2005-10-31 Arena Pharm Inc Receptor acoplato a proteina g orfao humano, rup3
ES2307482T3 (es) * 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
GB9912416D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9923177D0 (en) 1999-09-30 1999-12-01 Pfizer Ltd Novel polypeptide
IL139073A0 (en) 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
EP1176147A1 (en) 2000-07-28 2002-01-30 Pfizer Limited Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof
US6770645B2 (en) 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
US6784185B2 (en) 2001-03-16 2004-08-31 Pfizer Inc. Pharmaceutically active compounds
US20030095958A1 (en) 2001-04-27 2003-05-22 Bhisetti Govinda R. Inhibitors of bace
US20030003157A1 (en) 2001-06-06 2003-01-02 University Of Medicine & Dentistry Of New Jersey Collagen compositions and methods for making and using the same
WO2003014110A1 (en) 2001-08-08 2003-02-20 Takeda Chemical Industries, Ltd. Benzazepine derivative, process for producing the same, and use
EP1469830A2 (en) * 2002-02-01 2004-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
JPWO2003091216A1 (ja) 2002-04-25 2005-09-02 住友製薬株式会社 新規ピペリジン誘導体
GB0224919D0 (en) 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy
GB0230162D0 (en) 2002-12-24 2003-02-05 Metris Therapeutics Ltd Compounds useful in inhibiting angiogenesis
ES2268341T3 (es) 2003-03-05 2007-03-16 Maus S.P.A. Metodo para mecanizar un disco de freno.
GB0308333D0 (en) 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
MXPA05013474A (es) 2003-06-13 2006-03-09 Schering Ag Derivados de quinolilamida como antagonistas de ccr-5.
US7132426B2 (en) 2003-07-14 2006-11-07 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
KR20060036105A (ko) 2003-07-29 2006-04-27 제논 파마슈티칼스 인크. 피리딜 유도체 및 그의 치료제로서의 용도
FR2862647B1 (fr) 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
NZ547965A (en) 2003-12-24 2009-12-24 Prosidion Ltd 1,2,4-Oxadiazole derivatives as GPCR receptor agonists
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
AU2005251909A1 (en) 2004-06-08 2005-12-22 Nsab, Filial Af Neurosearch Sweden Ab, Sverige New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
PT1852433E (pt) 2004-10-29 2012-02-08 Zeria Pharm Co Ltd Derivados de carbazole, seus solvatos ou seus sais farmaceuticamente aceitáveis
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US8277495B2 (en) 2005-01-13 2012-10-02 Candela Corporation Method and apparatus for treating a diseased nail
AU2006216941B2 (en) 2005-02-16 2009-12-03 Pharmacopeia, Llc Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity
EP1888529A2 (en) 2005-05-18 2008-02-20 Wyeth 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
EP1888512A2 (en) 2005-06-06 2008-02-20 Smithkline Beecham Corporation Chemical compounds
CA2611216A1 (en) 2005-06-15 2006-12-21 Pfizer Limited 3-phenylazetidine derivatives as dopamine agonists
WO2007023507A2 (en) 2005-06-20 2007-03-01 Wockhardt Limited Oxazolidinones bearing antimicrobial activity composition and methods of preparation
JP5114395B2 (ja) 2005-06-30 2013-01-09 プロシディオン・リミテッド Gpcrアゴニスト
JP2008545008A (ja) 2005-06-30 2008-12-11 プロシディオン・リミテッド Gpcrアゴニスト
ATE429430T1 (de) 2005-09-16 2009-05-15 Arena Pharm Inc Stoffwechselmodulatoren und behandlung damit verbundener erkrankungen
BRPI0617207A2 (pt) 2005-09-29 2011-07-19 Sanofi Aventis derivados de fenil-1,2,4-oxadiazolona, processos para sua preparação e seu uso como produtos farmacêuticos
WO2007066189A2 (en) * 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
EP2043744A2 (en) 2006-07-13 2009-04-08 SmithKline Beecham Corporation Chemical compounds
US8343548B2 (en) * 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US20080103141A1 (en) 2006-08-30 2008-05-01 Biovitrum New compounds
EP2101741B1 (en) * 2006-10-17 2010-08-11 Bend Research, Inc. Solid dispersion comprising a poorly water soluble drug
EP2094683B1 (en) 2006-12-06 2011-10-12 GlaxoSmithKline LLC Bicyclic compounds and use as antidiabetics
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
ZA200904281B (en) * 2006-12-28 2010-08-25 Metabolex Inc Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
ES2352880T3 (es) 2007-03-08 2011-02-23 Irm Llc Compuestos y composiciones como moduladores de la actividad de gpr119.
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
JP2010533672A (ja) 2007-07-19 2010-10-28 エフ.ホフマン−ラ ロシュ アーゲー 新規ヘテロシクリル化合物およびケモカインアンタゴニストとしてのそれらの使用
EP2185544B1 (en) 2007-07-19 2014-11-26 Cymabay Therapeutics, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 for the treatment of diabetes and metabolic disorders
UY31232A1 (es) 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones
DK2019104T3 (da) 2007-07-19 2013-12-16 Sanofi Sa Cytotoksiske midler, der omfatter nye tomaymycinderivater, og terapeutisk anvendelse deraf
CN101801958B (zh) 2007-07-19 2014-01-29 默沙东公司 作为蛋白质激酶抑制剂的杂环酰胺化合物
FR2918986B1 (fr) 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
WO2009070869A1 (en) 2007-12-04 2009-06-11 Merck Frosst Canada Ltd. Renin inhibitors
CA2719507C (en) * 2008-03-31 2018-03-27 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
AU2009271414A1 (en) 2008-06-20 2010-01-21 Metabolex, Inc. Aryl GPR119 agonists and uses thereof
US8536176B2 (en) 2008-08-01 2013-09-17 Nippon Chemiphar Co., Ltd. GPR119 agonist
BRPI0919288A2 (pt) * 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110160222A1 (en) 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
CN102596177B (zh) 2009-07-01 2014-05-28 阿昂梅迪克斯公司 来源于有核哺乳动物细胞的微囊泡及其应用
EP2483281B1 (en) * 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
WO2011153435A1 (en) 2010-06-04 2011-12-08 Metabolex, Inc. Preparation of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
BR112012032248A2 (pt) 2010-06-23 2016-09-13 Metabolex Inc composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof

Similar Documents

Publication Publication Date Title
JP2013529637A5 (enExample)
JP2015527395A5 (enExample)
WO2012091153A3 (en) Orally disintegrating tablet
JP2014532638A5 (enExample)
JP2010090168A5 (enExample)
JP2017504611A5 (enExample)
JP2014167026A5 (enExample)
JP2005320354A5 (enExample)
AR103981A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención
HRP20171578T1 (hr) Čvrsta disperzija
JP2017523206A5 (enExample)
NZ605232A (en) Formulations of rifaximin and uses thereof
JP2017528503A5 (enExample)
US10004691B2 (en) Orally disintegrable tablet
JP2019510059A5 (enExample)
JP2012255026A5 (enExample)
JP2016539953A5 (enExample)
JP2017500332A (ja) 経口医薬組成物
JP2016510741A5 (enExample)
CN110123781A (zh) 含有药物的中空颗粒
CN104080446A (zh) 干包衣片
JP2017518985A (ja) アリサルタン・イソプロキシル固体分散体及び医薬組成物
TWI592154B (zh) Allisartan-based solid dispersions and pharmaceutical compositions containing the solid dispersions
JP2017502948A5 (enExample)
JP2014526508A5 (enExample)